

JC20 Rec'd PCT/PTO 29 APR 2005

IN THE UNITED STATES RECEIVING OFFICE (RO/US)  
Designated/Elected Office (DO/EO/US)

(#3)

U.S. National Stage of  
International Application No.: PCT/US03/34801  
International Filing Date: October 31, 2003  
Earliest Priority Date: November 1, 2002  
Applicants: deCODE genetics ehf., Inga Reynisdottir, Jeffrey R. Gulcher, Struan F. Grant and Gudmar Thorleifsson  
Title: Human Type II Diabetes Gene-Slit-3 Located on Chromosome 5q35  
Attorney's Docket No.: 2345.2046-007

Date: 29 APRIL 2005

EXPRESS MAIL LABEL NO. EV21488272 US

INFORMATION DISCLOSURE STATEMENT

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

under 37 CFR 1.129(a), or

(First/Second submission after Final Rejection)

under 37 CFR 1.97(b), or

(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

under 37 CFR 1.97(c) together with either:

a Statement under 37 CFR 1.97(e), as checked below, or

a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

under 37 CFR 1.97(d) together with:

a Statement under 37 CFR 1.97(e), as checked below, and

a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

Enclosed herewith is form PTO-1449:

Copies of the cited references are enclosed.

Copies of issued U.S. patents and published U.S. applications are not required and are not being provided.

Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]

The listed references were cited in the enclosed International Search Report in a counterpart foreign application.

The "concise explanation" requirement (non-English references) for reference(s) [ ] under 37 CFR 1.98(a)(3) is satisfied by:

- the explanation provided on the attached sheet.
- the explanation provided in the Specification.
- submission of the enclosed International Search Report.
- submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
- the enclosed English language abstract.

10/533365

JC20 Rec'd PCT/PTO 29 APR 2005

[ ] Applicant requests that the following non-published pending applications be considered:

Examiner's  
Initials

\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]  
\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]  
\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

Examiner

Date

[ ] A copy of each above-cited application, including the current claims, is enclosed, except any application filed on or after June 30, 2003, which has been scanned into the PTO's Image File Wrapper (IFW) system and is available to the examiner.

[ ] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

[ ] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.

[ ] Please charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is enclosed.

[X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Pamela A. Torpey  
Pamela A. Torpey  
Registration No.: 45,736  
Telephone: (978) 341-0036  
Facsimile: (978) 341-0136

Concord, MA 01742-9133  
Dated: 29 April 2005

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE STATEMENT  
IN AN APPLICATION

April 11, 2005

(Use several sheets if necessary)

ATTORNEY DOCKET NO.  
2345.2046-007FIRST NAME OF INVENTOR  
Inga ReynisdottirPCT APPLICATION NO.  
PCT/US03/24861INTERNATIONAL FILING DATE  
October 31, 2003

JC20 Rec'd PCT/PTO 29 APR 2005

#3

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AR	Kong, A., <i>et al.</i> , "A High-Resolution Recombination Map of the Human Genome," <i>Nat. Genet.</i> , 31(3): 241-247 (2002).
AS	Lindgren, C.M., <i>et al.</i> , "Contribution of Known and Unknown Susceptibility Genes to Early-Onset Diabetes in Scandinavia," <i>Diabetes</i> , 51(5): 1609-1617 (2002).
AT	Furuta, H., <i>et al.</i> , "Sequences of Human Hexokinase III cDNA and Assignment of the Human Hexokinase III Gene (HK3) to Chromosome Band 5q35.2 by Fluorescence in Situ Hybridization," <i>Genomics</i> , 36(1): 206-209 (1996).
AU	Itoh, A. , <i>et al.</i> , "Cloning and Expressions of Three Mammalian Homologues of <i>Drosophila</i> Slit Suggest Possible Roles for Slit in the Formation and Maintenance of the Nervous System," <i>Mol. Brain Res.</i> , 62(2): 175-186 (1998).

EXAMINER

DATE CONSIDERED